Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 3.183
Filter
1.
BMC Womens Health ; 24(1): 383, 2024 Jul 03.
Article in English | MEDLINE | ID: mdl-38961459

ABSTRACT

BACKGROUND: The role of bacterial contamination in the development and progression of endometriosis lesions is currently a hot topic for gynecologists. In this study, we decided to compare the endometrial cultures of women affected by endometriosis with those of non-endometriotic women, focusing on specific microbial pathogens. MATERIAL AND METHOD: In this cross-sectional case-control study, 30 women with endometriosis in stages 4 of the disease whose endometriosis was confirmed based on clinical, ultrasound, and histopathological findings, and 30 women without endometriosis who were candidates for surgery due to benign uterine diseases with regular menstrual cycle, underwent endometrial biopsy with Novak Kort in sterile conditions before starting their operation, and the results of their endometrial culture were analyzed and compared. RESULTS: Results of the study indicate that there were no significant differences in terms of age, BMI, smoking, education level, place of residency, use of the intrauterine device, or vaginal douche, and age of menarche between the case and control groups. The only demographic difference observed was in parity, where the control group had a significantly higher parity than the case group (P = 0.001). Out of the 60 cultures, only 15 samples were positive in the endometriosis group, and E. coli was the most prevalent species, with 10 (33.3%) samples testing positive for it. Klebsiella spp. and Enterobacteria spp. were also detected in 3 (10.0%) and 2 (6.7%) samples, respectively. The comparison between the two groups showed that only E. coli had a significant association with the presence of endometriosis (P = 0.001). There was no significant relationship between the location of endometriosis in the pelvic cavity and culture results. It was observed that parity among the E. coli negative group was significantly higher compared to the E. coli positive group (P < 0.001). CONCLUSION: Based on The high occurrence of E. coli in women with endometriosis, along with its potential involvement in the progression and/or recurrence of this condition, the researchers propose that treating women with endometriosis and recurrent IVF failure, as well as those with endometriosis recurrence after surgical treatment, with suitable antibiotics and repeated culture until the culture becomes negative, could be beneficial.


Subject(s)
Endometriosis , Escherichia coli Infections , Escherichia coli , Humans , Female , Endometriosis/microbiology , Endometriosis/complications , Case-Control Studies , Iran/epidemiology , Adult , Escherichia coli/isolation & purification , Cross-Sectional Studies , Escherichia coli Infections/epidemiology , Escherichia coli Infections/complications , Escherichia coli Infections/microbiology , Endometrium/microbiology , Endometrium/pathology , Klebsiella/isolation & purification
2.
BMC Nephrol ; 25(1): 200, 2024 Jun 18.
Article in English | MEDLINE | ID: mdl-38890600

ABSTRACT

Malakoplakia is a rare inflammatory disorder believed to result from a defect in macrophage phagocytic function triggering a granulomatous reaction. It can present with genitourinary, gastrointestinal, or cutaneous manifestations in immunocompromised or, less commonly, immunocompetent hosts. We describe a case of renal malakoplakia in a young, otherwise healthy patient presenting with nephromegaly and sepsis following an E. coli urinary tract infection. We discuss diagnosis and management, including antibiotic selection and the decision to pursue nephrectomy. This case highlights the potential for kidney recovery with prolonged antibiotic therapy in conjunction with adjunct immunomodulatory therapies and source control.


Subject(s)
Escherichia coli Infections , Malacoplakia , Urinary Tract Infections , Humans , Malacoplakia/complications , Malacoplakia/etiology , Urinary Tract Infections/complications , Urinary Tract Infections/drug therapy , Escherichia coli Infections/complications , Male , Anti-Bacterial Agents/therapeutic use , Adult , Female , Escherichia coli/isolation & purification
3.
J Med Case Rep ; 18(1): 300, 2024 Jul 01.
Article in English | MEDLINE | ID: mdl-38946001

ABSTRACT

BACKGROUND: Necrotizing myopathies and muscle necrosis can be caused by immune-mediated mechanisms, drugs, ischemia, and infections, and differential diagnosis may be challenging. CASE PRESENTATION: We describe a case of diabetic myonecrosis complicated by pyomyositis and abscess caused by Escherichia coli. A white woman in her late forties was admitted to the hospital with a 1.5 week history of bilateral swelling, weakness, and mild pain of the lower extremities and inability to walk. She had a history of type 1 diabetes complicated by diabetic retinopathy, neuropathy, nephropathy, and end-stage renal disease. C-reactive protein was 203 mg/l, while creatinine kinase was only mildly elevated to 700 IU/l. Magnetic resonance imaging of her lower limb muscles showed extensive edema, and muscle biopsy was suggestive of necrotizing myopathy with mild inflammation. No myositis-associated or myositis-specific antibodies were detected. Initially, she was suspected to have seronegative immune-mediated necrotizing myopathy, but later her condition was considered to be explained better by diabetic myonecrosis with multifocal involvement. Her symptoms alleviated without any immunosuppressive treatment. After a month, she developed new-onset and more severe symptoms in her right posterior thigh. She was diagnosed with emphysematous urinary tract infection and emphysematous myositis and abscess of the right hamstring muscle. Bacterial cultures of drained pus from abscess and urine were positive for Escherichia coli. In addition to abscess drainage, she received two 3-4-week courses of intravenous antibiotics. In the discussion, we compare the symptoms and findings typically found in pyomyositis, immune-mediated necrotizing myopathy, and diabetic myonecrosis (spontaneous ischemic necrosis of skeletal muscle among people with diabetes). All of these diseases may cause muscle weakness and pain, muscle edema in imaging, and muscle necrosis. However, many differences exist in their clinical presentation, imaging, histology, and extramuscular symptoms, which can be useful in determining diagnosis. As pyomyositis often occurs in muscles with pre-existing pathologies, the ischemic muscle has likely served as a favorable breeding ground for the E. coli in our case. CONCLUSIONS: Identifying the etiology of necrotizing myopathy is a diagnostic challenge and often requires a multidisciplinary assessment of internists, pathologists, and radiologists. Moreover, the presence of two rare conditions concomitantly is possible in cases with atypical features.


Subject(s)
Abscess , Anti-Bacterial Agents , Escherichia coli Infections , Magnetic Resonance Imaging , Necrosis , Pyomyositis , Female , Humans , Abscess/complications , Abscess/microbiology , Anti-Bacterial Agents/therapeutic use , Diabetes Mellitus, Type 1/complications , Escherichia coli/isolation & purification , Escherichia coli Infections/complications , Escherichia coli Infections/diagnosis , Pyomyositis/diagnosis , Pyomyositis/complications , Pyomyositis/microbiology , Urinary Tract Infections/complications , Urinary Tract Infections/diagnosis , Adult
4.
BMJ Case Rep ; 17(5)2024 May 22.
Article in English | MEDLINE | ID: mdl-38782428

ABSTRACT

A late middle-aged woman presented with a large, painful neck mass, with a history of rapid increase of size since 1 week and associated voice change, dyspnoea and odynophagia. Prior radiological investigation showed a multiloculated cystic mass in the left thyroid lobe. Fine needle aspiration revealed a predominant cluster of neutrophils. Blood investigations showed leucocytosis and high blood glucose levels suggestive of sepsis. The patient underwent surgical drainage of the thyroid abscess with total thyroidectomy which was managed through multidisciplinary teamwork between surgeons, haematologists, endocrinologists and anaesthesiologists. In addition, urine culture and thyroid pus culture both showed Escherichia coli growth suggestive of bacterial sepsis. The patient was treated successfully and made a complete recovery following surgery with normalisation of voice.


Subject(s)
Drainage , Sepsis , Thyroid Diseases , Thyroidectomy , Humans , Female , Sepsis/complications , Sepsis/microbiology , Drainage/methods , Middle Aged , Thyroid Diseases/complications , Thyroid Diseases/diagnosis , Thyroid Diseases/microbiology , Thyroid Diseases/surgery , Abscess/microbiology , Abscess/diagnosis , Abscess/complications , Escherichia coli Infections/complications , Escherichia coli Infections/diagnosis , Escherichia coli Infections/therapy , Thyroid Gland/pathology , Thyroid Gland/diagnostic imaging , Anti-Bacterial Agents/therapeutic use
5.
Georgian Med News ; (348): 78-80, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38807396

ABSTRACT

Escherichia coli is a gram-negative bacillus and considered to be the normal pathogen of intestinal and extraintestinal manifestations depending upon the strain. A variety of strains exist that are responsible for causing myriads of clinical presentation. E.coli O157: H7 being the most common and severe bacterial pathogen is the leading cause of bloody diarrhea. EHEC (Enterohemorrhagic E.coli) is responsible for causing severe complications like HC (Hemorrhagic colitis). Herein, we present the case of a young girl with E.coli O157:H7 infection and review the related literature. A previously healthy 37-year-old female presented with bloody diarrhea, fever, headache, and lower abdominal pain. As per history she had eaten a hamburger, denied any recent travel and absence of inflammatory bowel disease or bloody stools in family history. Physical examination revealed normal vital signs and the physical findings were unremarkable except for severe abdominal pain. Her stool was hem-occult positive. The complete blood count was within normal limits except neutrophilia and leukocytosis. An abdominal ultrasound showed thickened bowel loops consistent with colitis. First week of her hospital course, she continued to have bloody diarrhea and severe abdominal pain. Her final stool submitted to the laboratory on day 7 was consistent with a blood clot, following her developed low urine output and hematuria, with a serum creatinine of 2.1 mg/dl on day 5. Her renal symptoms were treated with fluids. She was given supportive treatment, and her platelet count and hemoglobin were stabilized. In early stages of bloody diarrhea, parental hydration plays a major role in accelerating volume expansion. Rapid stool analysis for these bacteria can alert specialists to deal with severe complications like HUS.


Subject(s)
Escherichia coli Infections , Hemolytic-Uremic Syndrome , Humans , Female , Adult , Hemolytic-Uremic Syndrome/microbiology , Hemolytic-Uremic Syndrome/diagnosis , Escherichia coli Infections/microbiology , Escherichia coli Infections/diagnosis , Escherichia coli Infections/complications , Diarrhea/microbiology , Escherichia coli O157/isolation & purification , Abdominal Pain/microbiology , Abdominal Pain/etiology , Enterohemorrhagic Escherichia coli/pathogenicity , Enterohemorrhagic Escherichia coli/isolation & purification
6.
Pediatr Nephrol ; 39(8): 2459-2465, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38589699

ABSTRACT

BACKGROUND: Hemolytic uremic syndrome (HUS) is an important cause of acute kidney injury in children. HUS is known as an acute disease followed by complete recovery, but patients may present with kidney abnormalities after long periods of time. This study evaluates the long-term outcome of Shiga toxin-producing Escherichia coli-associated HUS (STEC-HUS) in pediatric patients, 10 years after the acute phase of disease to identify risk factors for long-term sequelae. METHODS: Over a 6-year period, 619 patients under 18 years of age with HUS (490 STEC-positive, 79%) were registered in Austria and Germany. Long-term follow-up data of 138 STEC-HUS-patients were available after 10 years for analysis. RESULTS: A total of 66% (n = 91, 95% CI 0.57-0.73) of patients fully recovered showing no sequelae after 10 years. An additional 34% (n = 47, 95% CI 0.27-0.43) presented either with decreased glomerular filtration rate (24%), proteinuria (23%), hypertension (17%), or neurological symptoms (3%). Thirty had sequelae 1 year after STEC-HUS, and the rest presented abnormalities unprecedented at the 2-year (n = 2), 3-year (n = 3), 5-year (n = 3), or 10-year (n = 9) follow-up. A total of 17 patients (36.2%) without kidney abnormalities at the 1-year follow-up presented with either proteinuria, hypertension, or decreased eGFR in subsequent follow-up visits. Patients needing extracorporeal treatments during the acute phase were at higher risk of presenting symptoms after 10 years (p < 0.05). CONCLUSIONS: Patients with STEC-HUS should undergo regular follow-up, for a minimum of 10 years following their index presentation, due to the risk of long-term sequelae of their disease. An initial critical illness, marked by need of kidney replacement therapy or plasma treatment may help predict poor long-term outcome.


Subject(s)
Escherichia coli Infections , Hemolytic-Uremic Syndrome , Shiga-Toxigenic Escherichia coli , Humans , Hemolytic-Uremic Syndrome/microbiology , Hemolytic-Uremic Syndrome/therapy , Hemolytic-Uremic Syndrome/complications , Hemolytic-Uremic Syndrome/epidemiology , Shiga-Toxigenic Escherichia coli/isolation & purification , Male , Female , Child , Escherichia coli Infections/microbiology , Escherichia coli Infections/complications , Escherichia coli Infections/epidemiology , Escherichia coli Infections/diagnosis , Child, Preschool , Follow-Up Studies , Adolescent , Infant , Germany/epidemiology , Risk Factors , Glomerular Filtration Rate , Austria/epidemiology , Time Factors , Proteinuria/etiology , Proteinuria/microbiology , Proteinuria/diagnosis
7.
Clin Med (Lond) ; 24(2): 100036, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38588916

ABSTRACT

A 76-year-old Malay female presented with 2 days history of fever and vomiting. She was found to have Escherichia coli and Klebsiella pneumoniae bacteraemia with no clear intra-abdominal cause on the initial computed tomography of the abdomen and pelvis (CTAP). She clinically improved with 2 weeks duration of intravenous meropenem. She subsequently developed septic shock and a repeated CTAP demonstrated increased hepatic parenchymal density with extensive parenchymal calcifications. Curvilinear calcifications were seen in the paraspinal and pelvic musculature.


Subject(s)
Calcinosis , Humans , Female , Aged , Calcinosis/diagnostic imaging , Sepsis/microbiology , Tomography, X-Ray Computed , Liver Diseases/diagnostic imaging , Klebsiella pneumoniae/isolation & purification , Klebsiella Infections/diagnosis , Klebsiella Infections/complications , Klebsiella Infections/drug therapy , Escherichia coli Infections/complications , Escherichia coli Infections/diagnosis , Escherichia coli Infections/drug therapy , Muscular Diseases/diagnostic imaging , Anti-Bacterial Agents/therapeutic use , Meropenem/therapeutic use , Meropenem/administration & dosage
8.
J Int Med Res ; 52(4): 3000605241244756, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38661095

ABSTRACT

Pylephlebitis, which is a type of septic thrombophlebitis of the portal vein, is a rare and life-threatening complication that commonly occurs following appendicitis. However, nonspecific abdominal complaints and fever can impede the diagnosis of pylephlebitis. Timely use of appropriate antibiotics and anticoagulants is paramount for treating this condition. We present a case of pylephlebitis and septic shock caused by acute nonperforated appendicitis. A 32-year-old man presented with migratory right lower abdominal pain. Blood cultures showed the presence of Escherichia coli. Blood test results showed increased bilirubin concentrations and coagulation factor abnormalities. A computed tomographic abdominal scan showed that the portal vein had a widened intrinsic diameter. After intensive care treatment with antibiotics, antishock therapy, anticoagulants, and other supportive treatments, the infection was monitored, the abdominal pain disappeared, and the jaundice subsided. Laparoscopic appendectomy was performed. Histopathology showed acute suppurative appendicitis, and no abnormalities were observed during the follow-up period after discharge. A multidisciplinary approach is mandatory for the decision-making process in the presence of pylephlebitis caused by appendicitis to obtain a correct diagnosis and prompt treatment. Similarly, the timing of appendectomy is important for minimizing intra- and postoperative complications.


Subject(s)
Appendicitis , Portal Vein , Shock, Septic , Thrombophlebitis , Humans , Appendicitis/complications , Appendicitis/surgery , Appendicitis/diagnosis , Male , Adult , Thrombophlebitis/diagnosis , Thrombophlebitis/etiology , Thrombophlebitis/microbiology , Shock, Septic/etiology , Shock, Septic/microbiology , Portal Vein/pathology , Anti-Bacterial Agents/therapeutic use , Appendectomy , Tomography, X-Ray Computed , Escherichia coli/isolation & purification , Escherichia coli Infections/complications , Escherichia coli Infections/diagnosis , Acute Disease , Abdominal Pain/etiology
9.
Saudi Med J ; 45(3): 241-251, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38438206

ABSTRACT

OBJECTIVES: To compare the prognosis of bacteremic pneumonia caused by Klebsiella pneumoniae (K. pneumoniae) and Escherichia coli (E. coli) pathogens. METHODS: A retrospective analysis was carried out on the clinical data of 162 patients who were diagnosed with bacterial pneumonia caused by either K. pneumoniae or E. coli between 2016-2019. The primary outcome of the analysis was the patients' 30-day mortality rate. RESULTS: There were 82 patients in the E. coli bacteremic pneumonia (E. coli-BP) group and 80 patients in the K. pneumoniae bacteremic pneumonia (KP-BP) group. The 30-day mortality rate was 43.75% (n=35/80) in the KP-BP group and 21.95% (n=18/82) in the E. coli-BP group (p<0.001). Following the adjustment for confounding variables in 4 distinct models, the hazard ratios for the primary outcome in KP-BP were determined to be 0.70 (95% confidence interval [CI]: [0.44-1.02]) in Model 1, 0.72 (95% CI: [0.46-1.14]) in Model 2, 0.99 (95% CI: [0.57-1.73]) in Model 3, and 1.22 (95% CI: [0.69-2.18]) in Model 4. CONCLUSION: Patients diagnosed with KP-BP exhibited a similar prognosis as those diagnosed with E. coli-BP. For patients with KP-BP, the risk of mortality was significantly higher for those who were in the intensive care unit, were infected with carbapenem-resistant strains, or had a high sequential organ failure assessment score. In patients with E. coli-BP, the Pitt bacteremia score was strongly associated with the 30-day mortality rate.


Subject(s)
Bacteremia , Escherichia coli Infections , Pneumonia , Humans , Klebsiella pneumoniae , Escherichia coli , Retrospective Studies , Escherichia coli Infections/complications
10.
Clin J Gastroenterol ; 17(3): 472-476, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38528197

ABSTRACT

Escherichia coli-associated native-valve infective endocarditis is a rare disease that affects elderly patients with underlying risk factors such as diabetes mellitus, malignancy, and renal failure. Long-term use of calcium polystyrene sulfonate is a potential risk factor for gastrointestinal mucosal damage or even colorectal ulcers. Herein, we describe a fatal case of a 66-year-old Japanese man with diabetes mellitus and renal failure who was prescribed calcium polystyrene sulfonate (CPS) for 11 years and developed a CPS-induced rectal ulcer, leading to E. coli native-valve infective endocarditis. The patient was admitted to our hospital due to acute-onset impaired consciousness. As a result of the systemic investigation, he was diagnosed with E. coli bacteremia accompanied by multiple cerebral infarctions and an acute hemorrhagic rectal ulcer. Transesophageal echocardiography revealed a 20-mm vegetative structure on the mitral valve, resulting in a final diagnosis of E. coli-associated infective endocarditis. After rectal resection, mitral valve replacement surgery was performed; however, the patient died shortly after surgery. Pathological findings of the resected rectum showed deposition of a basophilic crystalline material suggesting the presence of CPS. Our case highlights the potential risk of colorectal ulcers in a long-term CPS user, which can trigger bacterial translocation and endocarditis as fatal complications.


Subject(s)
Endocarditis, Bacterial , Escherichia coli Infections , Polystyrenes , Rectal Diseases , Ulcer , Humans , Male , Aged , Polystyrenes/adverse effects , Fatal Outcome , Escherichia coli Infections/complications , Ulcer/etiology , Ulcer/microbiology , Endocarditis, Bacterial/complications , Rectal Diseases/microbiology , Mitral Valve/surgery , Escherichia coli
11.
Acta Gastroenterol Belg ; 87(1): 37-39, 2024.
Article in English | MEDLINE | ID: mdl-38431789

ABSTRACT

Acute colitis is a common feature of infection with Shiga-toxin producing Escherichia coli (STEC) and can mimic acute severe ulcerative colitis. Early recognition is important as there is a risk of developing Shiga toxin-induced haemolytic uremic syndrome (STEC-HUS), defined by the triad of microangiopathic haemolytic anemia, thrombocytopenia and organ damage. In severe cases STEC-HUS can cause severe neurological complications and can be fatal. We present a patient with a medical history of refractory ulcerative colitis, where making the diagnosis of STEC-HUS was challenging since the initial clinical presentation was difficult to differentiate from a flare of ulcerative colitis. This case illustrates that STEC induced colitis can mimic acute severe ulcerative colitis. This finding is of utmost clinical importance because of the potential life-threatening complications of STEC-HUS. Therefore it should be excluded promptly in patients with acute severe ulcerative colitis by using multiplex-PCR assay on a faecal sample.


Subject(s)
Colitis, Ulcerative , Colitis , Escherichia coli Infections , Hemolytic-Uremic Syndrome , Shiga-Toxigenic Escherichia coli , Humans , Escherichia coli Infections/complications , Escherichia coli Infections/diagnosis , Colitis, Ulcerative/complications , Colitis, Ulcerative/diagnosis , Hemolytic-Uremic Syndrome/diagnosis , Hemolytic-Uremic Syndrome/complications , Colitis/diagnosis
12.
J Virol ; 98(3): e0151223, 2024 Mar 19.
Article in English | MEDLINE | ID: mdl-38415626

ABSTRACT

H9N2 avian influenza is a low-pathogenic avian influenza circulating in poultry and wild birds worldwide and frequently contributes to chicken salpingitis that is caused by avian pathogenic Escherichia coli (APEC), leading to huge economic losses and risks for food safety. Currently, how the H9N2 virus contributes to APEC infection and facilitates salpingitis remains elusive. In this study, in vitro chicken oviduct epithelial cell (COEC) model and in vivo studies were performed to investigate the role of H9N2 viruses on secondary APEC infection, and we identified that H9N2 virus enhances APEC infection both in vitro and in vivo. To understand the mechanisms behind this phenomenon, adhesive molecules on the cell surface facilitating APEC adhesion were checked, and we found that H9N2 virus could upregulate the expression of fibronectin, which promotes APEC adhesion onto COECs. We further investigated how fibronectin expression is regulated by H9N2 virus infection and revealed that transforming growth factor beta (TGF-ß) signaling pathway is activated by the NS1 protein of the virus, thus regulating the expression of adhesive molecules. These new findings revealed the role of H9N2 virus in salpingitis co-infected with APEC and discovered the molecular mechanisms by which the H9N2 virus facilitates APEC infection, offering new insights to the etiology of salpingitis with viral-bacterial co-infections.IMPORTANCEH9N2 avian influenza virus (AIV) widely infects poultry and is sporadically reported in human infections. The infection in birds frequently causes secondary bacterial infections, resulting in severe symptoms like pneumonia and salpingitis. Currently, the mechanism that influenza A virus contributes to secondary bacterial infection remains elusive. Here we discovered that H9N2 virus infection promotes APEC infection and further explored the underlying molecular mechanisms. We found that fibronectin protein on the cell surface is vital for APEC adhesion and also showed that H9N2 viral protein NS1 increased the expression of fibronectin by activating the TGF-ß signaling pathway. Our findings offer new information on how AIV infection promotes APEC secondary infection, providing potential targets for mitigating severe APEC infections induced by H9N2 avian influenza, and also give new insights on the mechanisms on how viruses promote secondary bacterial infections in animal and human diseases.


Subject(s)
Escherichia coli Infections , Influenza A Virus, H9N2 Subtype , Influenza in Birds , Poultry Diseases , Salpingitis , Animals , Female , Humans , Chickens , Escherichia coli , Fibronectins/metabolism , Influenza A Virus, H9N2 Subtype/physiology , Influenza in Birds/complications , Oviducts/metabolism , Poultry , Poultry Diseases/metabolism , Poultry Diseases/virology , Salpingitis/metabolism , Salpingitis/veterinary , Salpingitis/virology , Transforming Growth Factor beta/metabolism , Viral Proteins/metabolism , Escherichia coli Infections/complications , Escherichia coli Infections/veterinary
13.
J Transl Med ; 22(1): 17, 2024 01 04.
Article in English | MEDLINE | ID: mdl-38178089

ABSTRACT

BACKGROUND: Hemolysis is a cardinal feature of hemolytic uremic syndrome (HUS) and during hemolysis excess arginase 1 is released from red blood cells. Increased arginase activity leads to reduced L-arginine, as it is converted to urea and L-ornithine, and thereby reduced nitric oxide bioavailability, with secondary vascular injury. The objective of this study was to investigate arginase release in HUS patients and laboratory models and correlate arginase levels to hemolysis and kidney injury. METHODS: Two separate cohorts of patients (n = 47 in total) with HUS associated with Shiga toxin-producing enterohemorrhagic E. coli (EHEC) and pediatric controls (n = 35) were investigated. Two mouse models were used, in which mice were either challenged intragastrically with E. coli O157:H7 or injected intraperitoneally with Shiga toxin 2. An in vitro model of thrombotic microangiopathy was developed in which Shiga toxin 2- and E. coli O157 lipopolysaccharide-stimulated human blood cells combined with ADAMTS13-deficient plasma were perfused over glomerular endothelial cells. Two group statistical comparisons were performed using the Mann-Whitney test, multiple groups were compared using the Kruskal-Wallis test followed by Dunn's procedure, the Wilcoxon signed rank test was used for paired data, or linear regression for continuous variables. RESULTS: HUS patients had excessively high plasma arginase 1 levels and activity (conversion of L-arginine to urea and L-ornithine) during the acute phase, compared to remission and controls. Arginase 1 levels correlated with lactate dehydrogenase activity, indicating hemolysis, as well as the need for dialysis treatment. Patients also exhibited high levels of plasma alpha-1-microglobulin, a heme scavenger. Both mouse models exhibited significantly elevated plasma arginase 1 levels and activity. Plasma arginase 1 levels correlated with lactate dehydrogenase activity, alpha-1-microglobulin and urea levels, the latter indicative of kidney dysfunction. In the in vitro model of thrombotic microangiopathy, bioactive arginase 1 was released and levels correlated to the degree of hemolysis. CONCLUSIONS: Elevated red blood cell-derived arginase was demonstrated in HUS patients and in relevant in vivo and in vitro models. The excessively high arginase levels correlated to the degree of hemolysis and kidney dysfunction. Thus, arginase inhibition should be investigated in HUS.


Subject(s)
Escherichia coli Infections , Escherichia coli O157 , Hemolytic-Uremic Syndrome , Renal Insufficiency , Thrombotic Microangiopathies , Humans , Child , Animals , Mice , Shiga Toxin 2 , Endothelial Cells , Hemolysis , Arginase , Hemolytic-Uremic Syndrome/complications , Hemolytic-Uremic Syndrome/therapy , Erythrocytes , Thrombotic Microangiopathies/complications , Urea , Arginine , Ornithine , Lactate Dehydrogenases , Escherichia coli Infections/complications , Escherichia coli Infections/therapy
14.
BMJ Case Rep ; 17(1)2024 Jan 18.
Article in English | MEDLINE | ID: mdl-38238162

ABSTRACT

Shiga toxin (Stx)-producing Escherichia coli-mediated haemolytic uraemic syndrome is a primary thrombotic microangiopathy, typified by the development of microangiopathic haemolytic anaemia, thrombocytopaenia and acute renal failure. It is a leading cause of acute renal failure in paediatrics, with a second peak in prevalence in adults over the age of 60. Presentations of Stx-producing E. coli-mediated haemolytic uraemic syndrome in young adults are rare. We present the case of a previously well female in her early 30s presenting with Stx-producing E. coli-mediated haemolytic uraemic syndrome with severe renal and neurological manifestations. Eculizumab was administered due to the severity of presentation and disease trajectory refractory to initial supportive therapy. A significant clinical and biochemical improvement was observed following eculizumab.


Subject(s)
Acute Kidney Injury , Antibodies, Monoclonal, Humanized , Escherichia coli Infections , Hemolytic-Uremic Syndrome , Shiga-Toxigenic Escherichia coli , Humans , Child , Female , Shiga Toxin/therapeutic use , Hemolytic-Uremic Syndrome/drug therapy , Escherichia coli Infections/complications , Escherichia coli Infections/drug therapy , Acute Kidney Injury/drug therapy , Acute Kidney Injury/etiology
15.
Pediatr Nephrol ; 39(6): 1885-1891, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38189960

ABSTRACT

BACKGROUND: The gastrointestinal (GI) tract represents one of the main targets of typical hemolytic uremic syndrome (HUS) in children. In this observational study, we tried to establish (1) the main features of GI complications during STEC-HUS and (2) the relationship between Escherichia coli serotypes and Shiga toxin (Stx) variants with hepatopancreatic involvement. METHODS: A total of 79 STEC-HUS patients were admitted to our pediatric nephrology department between January 2012 and June 2021. Evidence of intestinal, hepatobiliary, and pancreatic involvements was reported for each patient, alongside demographic, clinical, and laboratory features. Frequency of gastrointestinal complications across groups of patients infected by specific E. coli serotypes and Stx gene variants was evaluated. RESULTS: Six patients developed a bowel complication: two developed rectal prolapse, and four developed bowel perforation which resulted in death for three of them and in bowel stenosis in one patient. Acute pancreatitis was diagnosed in 13 patients. An isolated increase in pancreatic enzymes and/or liver transaminases was observed in 41 and 15 patients, respectively. Biliary sludge was detected in three, cholelithiasis in one. Forty-seven patients developed direct hyperbilirubinemia. Neither E. coli serotypes nor Shiga toxin variants correlated with hepatic or pancreatic involvement. CONCLUSIONS: During STEC-HUS, GI complications are common, ranging from self-limited elevation of laboratory markers to bowel perforation, a severe complication with a relevant impact on morbidity and mortality. Hepatopancreatic involvement is frequent, but usually short-lasting and self-limiting.


Subject(s)
Escherichia coli Infections , Hemolytic-Uremic Syndrome , Intestinal Perforation , Pancreatitis , Shiga-Toxigenic Escherichia coli , Child , Humans , Escherichia coli Infections/complications , Acute Disease , Hemolytic-Uremic Syndrome/complications , Shiga Toxin , Shiga-Toxigenic Escherichia coli/genetics
16.
Pediatr Nephrol ; 39(6): 1901-1907, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38240870

ABSTRACT

BACKGROUND: Shiga toxin-producing E. coli-hemolytic uremic syndrome (STEC-HUS) is associated with high morbidity and relevant mortality. Previous small studies showed that volume expansion could improve the course and outcome of STEC-HUS. The aim of this single-center study was to evaluate the effect of volume expansion on the clinical course and outcome in STEC-HUS. METHODS: Data of pediatric patients with STEC-HUS were analyzed retrospectively. Course and outcome of patients treated with volume expansion (VE) from 2019 to 2022 (n = 38) were compared to historical controls (HC) from 2009 to 2018 (n = 111). RESULTS: Patients in the VE group had a significant relative median weight gain compared to HC (7.8% (3.4-11.3) vs. 1.2% (- 0.7-3.9), p < 0.0001) 48 h after admission. The need for dialysis was not reduced by VE (VE 21/38 (55.3%) vs. HC 64/111 (57.7%), p = 0.8). However, central nervous system involvement (impairment of consciousness, seizures, focal neurological deficits, and/or visual disturbances) was significantly reduced (VE 6/38 (15.8%) vs. HC 38/111 (34.2%), p = 0.039). None of the patients in the VE group died or developed chronic kidney disease (CKD) stage 5, whereas in the HC group, three patients died and three patients had CKD stage 5 at discharge. CONCLUSIONS: This study suggests that volume expansion may be associated with the mitigation of the acute course of STEC-HUS, especially severe neurological involvement and the development of CKD. Prospective trials should lead to standardized protocols for volume expansion in children with STEC-HUS.


Subject(s)
Escherichia coli Infections , Hemolytic-Uremic Syndrome , Kidney Failure, Chronic , Shiga-Toxigenic Escherichia coli , Child , Humans , Shiga Toxin , Escherichia coli Infections/complications , Retrospective Studies , Prospective Studies , Renal Dialysis , Hemolytic-Uremic Syndrome/complications , Kidney Failure, Chronic/complications
17.
Pediatr Nephrol ; 39(2): 603-607, 2024 Feb.
Article in English | MEDLINE | ID: mdl-37474629

ABSTRACT

BACKGROUND: Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome (HUS) classically presents with diarrhea. Absence of diarrheal prodrome increases suspicion for atypical HUS (aHUS). Inability to obtain a fecal specimen for culture or culture-independent testing limits the ability to differentiate STEC-HUS and aHUS. CASE-DIAGNOSIS/TREATMENT: Our patient presented with abdominal pain and constipation, and evaluation of pallor led to a diagnosis of HUS. There was a complete absence of diarrhea during the disease course. Lack of fecal specimen for several days delayed testing for STEC. Treatment for atypical HUS was initiated with complement-blockade therapy. PCR-testing for Shiga toxin from fecal specimen later returned positive. Alternative complement-pathway testing did not identify a causative genetic variant or anti-Factor H antibody. A diagnosis of STEC-HUS was assigned, and complement-blockade therapy was stopped. CONCLUSION: Diagnosis of aHUS remains a diagnosis of exclusion, whereby other causes of HUS are eliminated with reasonable certainty. Exclusion of STEC is necessary and relies on testing availability and recognition of testing limitations. Diarrhea-negative STEC-HUS remains a minority of cases, and future research is needed to explore the clinical characteristics of these patients.


Subject(s)
Atypical Hemolytic Uremic Syndrome , Escherichia coli Infections , Shiga-Toxigenic Escherichia coli , Humans , Atypical Hemolytic Uremic Syndrome/complications , Atypical Hemolytic Uremic Syndrome/diagnosis , Atypical Hemolytic Uremic Syndrome/therapy , Diarrhea/diagnosis , Diarrhea/etiology , Complement Pathway, Alternative , Constipation/complications , Escherichia coli Infections/complications , Escherichia coli Infections/diagnosis , Escherichia coli Infections/drug therapy
19.
J Nephrol ; 37(1): 181-186, 2024 Jan.
Article in English | MEDLINE | ID: mdl-37314614

ABSTRACT

Clostridium septicum (C. septicum) is a zoonotic bacillus found in 2.8% of healthy human stools. In humans, it can cause serious infections such as bacteremia, myonecrosis, and encephalitis by spreading through the bloodstream. Reports of Shiga toxin-producing Escherichia Coli-related hemolytic-uremic syndrome complicated by C. septicum superinfection are rare, likely because colonic microangiopathic lesions by Shiga toxin-producing Escherichia Coli facilitate bacterial dissemination. Only 13 cases of Shiga toxin-producing Escherichia Coli-related hemolytic-uremic syndrome with C. septicum superinfection have been reported to date, according to our litterature review, with a 50% mortality rate. The lack of clinico-laboratory clues suggesting this condition makes the diagnosis challenging. For these reasons C. septicum superinfection usually goes undiagnosed in patients with Shiga toxin-producing Escherichia Coli-related hemolytic-uremic syndrome, and results in unfavorable outcomes. In this paper, we describe the case of a 5-year-old girl admitted for Shiga toxin-producing Escherichia Coli-related hemolytic-uremic syndrome who developed C. septicum coinfection leading to a fatal outcome. We carried out a review of the available literature on C. septicum infection complicating Shiga toxin-producing Escherichia Coli-related hemolytic-uremic syndrome and we compared the clinical features of the observed cases with those of an historical cohort of uncomplicated Shiga toxin-producing Escherichia Coli-related hemolytic-uremic syndrome. The mechanisms of superinfection are still unclear and clinical features are indistinguishable from those of uncomplicated Shiga toxin-producing Escherichia Coli-related hemolytic-uremic syndrome. However, rapid deterioration of clinical conditions and evidence of neurological involvement, associated with abnormal radiological findings, require immediate management. Although therapeutic approaches have not been directly compared, neurosurgical treatment of amenable lesions may improve the clinical outcome of patients with C. septicum-hemolytic-uremic syndrome.


Subject(s)
Clostridium septicum , Escherichia coli Infections , Hemolytic-Uremic Syndrome , Shiga-Toxigenic Escherichia coli , Superinfection , Female , Humans , Child, Preschool , Escherichia coli Infections/complications , Escherichia coli Infections/diagnosis , Superinfection/complications , Hemolytic-Uremic Syndrome/complications , Hemolytic-Uremic Syndrome/diagnosis , Hemolytic-Uremic Syndrome/therapy
20.
J Am Vet Med Assoc ; 262(2): 232-240, 2024 Feb 01.
Article in English | MEDLINE | ID: mdl-37972477

ABSTRACT

OBJECTIVE: To describe the clinical findings, microbiological data, treatment, and outcome of a population of cats with suspected acute pyelonephritis (APN). ANIMALS: 32 client-owned cats. CLINICAL PRESENTATION AND PROCEDURES: Retrospective case series from 2 veterinary teaching hospitals between January 1, 2014, and December 31, 2020. Cats were included if they had a positive bacterial urine culture and a clinical diagnosis of acute kidney injury. RESULTS: Older female cats with underlying chronic kidney disease have a higher probability to develop bacterial culture-positive acute kidney injury or APN. Escherichia coli was the most commonly cultured bacterial species, and E coli isolates with susceptibility testing were resistant to amoxicillin-clavulanate but susceptible to fluoroquinolones or third-generation cephalosporins. Of the 20 cats with available follow-up information in the medical record, 14 were alive at 3 months after hospital discharge. Markers of renal function including creatinine (P = .008), BUN (P = .005), and phosphorus (P < .001) at the time of presentation were all higher in nonsurvivors compared with survivors. CLINICAL RELEVANCE: The survival rate with feline APN is higher than previous reports of acute kidney injury when all etiologies are considered. Nonsurvivors had more pronounced azotemia upon initial presentation. Amoxicillin-clavulanate was a poor empirical antimicrobial in this cohort based on the microbiological data.


Subject(s)
Acute Kidney Injury , Cat Diseases , Escherichia coli Infections , Pyelonephritis , Humans , Cats , Animals , Female , Escherichia coli , Anti-Bacterial Agents/therapeutic use , Escherichia coli Infections/complications , Escherichia coli Infections/drug therapy , Escherichia coli Infections/veterinary , Penicillins/therapeutic use , Retrospective Studies , Pyelonephritis/drug therapy , Pyelonephritis/veterinary , Pyelonephritis/epidemiology , Amoxicillin-Potassium Clavulanate Combination/therapeutic use , Prognosis , Acute Kidney Injury/veterinary , Cat Diseases/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL